{"commentary":{"count":27,"free_build_floor":8,"listing_floor":3,"by_channel":{"podcast":14,"youtube":11,"x_thread":2},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT02737501\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"ALTA-1L","nct_id":"NCT02737501","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=alta-1l-nct02737501. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"ALTA-1L","arms":[{"description":"Brigatinib 90 mg, tablets, orally, QD for first 7 days followed by 180 mg, orally, QD, in each 28-day cycle until PD, intolerable toxicity, consent withdrawal, or death (The median duration of exposure was 34.86 months).","label":"Randomized Phase: Brigatinib 90 mg QD/180 QD","type":"EXPERIMENTAL"},{"description":"Crizotinib 250 mg, tablets, BID in each 28-day cycle until disease progression, intolerable toxicity, consent withdrawal, or death (The median duration of exposure was 9.26 months).","label":"Randomized Phase: Crizotinib 250 mg BID","type":"ACTIVE_COMPARATOR"},{"description":"Participants who experienced PD as assessed by the BIRC or received radiotherapy to the brain while on 'Crizotinib 250 mg BID' therapy in Randomized Phase were crossed over. Following 10-day washout period, crossover participants received brigatinib 90 mg, tablets, orally, QD for first 7 days followed by 180 mg, tablets, orally, QD in each 28-day cycle up to end of the study (The median duration of exposure was 17.25 months).","label":"Crossover Phase: Brigatinib 90 mg QD/180 mg QD","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2021-01-29","type":"ACTUAL"},"conditions":["Non-small Cell Lung Cancer","Lung Cancer","Advanced Malignancies","Carcinoma"],"enrollment":{"count":275,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Brigatinib","type":"DRUG"},{"name":"Crizotinib","type":"DRUG"}],"last_update":"2021-08-20","lead_sponsor":"Ariad Pharmaceuticals","official_title":"A Phase 3 Multicenter Open-label Study of Brigatinib (AP26113) Versus Crizotinib in Patients With ALK-positive Advanced Lung Cancer","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2020-07-28","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression-free Survival (PFS)","timeFrame":"Up to end of study (Up to 56 months)"}],"references":[{"citation":"Al Tawil A, Lauseker M, Mansmann U. Estimating causal effects on quality of life under treatment discontinuation: the ALTA-1L trial. J Clin Epidemiol. 2026 May;193:112189. doi: 10.1016/j.jclinepi.2026.112189. Epub 2026 Feb 23.","pmid":"41740899","type":"DERIVED"},{"citation":"Ahn MJ, Delmonte A, Ghosh S, Hochmair M, Yang TY, Yang JC, Han JY, Hansen KH, Wu Y, Wan Y, Lin HM, Kretz J, Hupf B, Kurec AM, Churchill EN, Fram RJ, Cabasag CJ, Goriya V, Zhao Y, Campelo MRG. Real-world treatment patterns and subsequent treatment effectiveness following frontline brigatinib in the ALTA-1L trial. Future Oncol. 2025 Dec;21(30):3935-3945. doi: 10.1080/14796694.2025.2592527. Epub 2025 Dec 18.","pmid":"41410381","type":"DERIVED"},{"citation":"Al Tawil A, McGrath S, Ristl R, Mansmann U. Addressing treatment switching in the ALTA-1L trial with g-methods: exploring the impact of model specification. BMC Med Res Methodol. 2024 Dec 20;24(1):314. doi: 10.1186/s12874-024-02437-6.","pmid":"39707229","type":"DERIVED"},{"citation":"Camidge DR, Kim HR, Ahn MJ, Yang JCH, Han JY, Hochmair MJ, Lee KH, Delmonte A, Garcia Campelo MR, Kim DW, Griesinger F, Felip E, Califano R, Spira A, Gettinger SN, Tiseo M, Lin HM, Gupta N, Hanley MJ, Ni Q, Zhang P, Popat S. Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial. J Clin Oncol. 2020 Nov 1;38(31):3592-3603. doi: 10.1200/JCO.20.00505. Epub 2020 Aug 11.","pmid":"32780660","type":"DERIVED"},{"citation":"Camidge DR, Kim HR, Ahn MJ, Yang JC, Han JY, Lee JS, Hochmair MJ, Li JY, Chang GC, Lee KH, Gridelli C, Delmonte A, Garcia Campelo R, Kim DW, Bearz A, Griesinger F, Morabito A, Felip E, Califano R, Ghosh S, Spira A, Gettinger SN, Tiseo M, Gupta N, Haney J, Kerstein D, Popat S. Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2018 Nov 22;379(21):2027-2039. doi: 10.1056/NEJMoa1810171. Epub 2018 Sep 25.","pmid":"30280657","type":"DERIVED"},{"citation":"Gainor JF, Shaw AT. J-ALEX: alectinib versus crizotinib in ALK-positive lung cancer. Lancet. 2017 Jul 1;390(10089):3-4. doi: 10.1016/S0140-6736(17)31074-7. Epub 2017 May 10. No abstract available.","pmid":"28501139","type":"DERIVED"}],"start_date":{"date":"2016-05-26","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants","url":"https://clinicaltrials.gov/study/NCT02737501"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/alta-1l-nct02737501"}